Scinai Immunotherapeutics

Historical price data

Scinai Immunotherapeutics Ltd. is a clinical-stage biotech company with a dual mission: advancing its own pipeline of antibody therapies for infectious and autoimmune diseases while operating a contract development and manufacturing organization (CDMO) to fund its research. Its key strategic asset is a state-of-the-art cGMP biologics manufacturing facility in Jerusalem, providing end-to-end control from discovery to production. The company's public listings on NASDAQ (SCNI) and the Tel Aviv Stock Exchange support its goal of leveraging service revenue to de-risk and accelerate its proprietary drug development programs.

Integrated antibody discovery, engineering, and cGMP manufacturing platform, featuring a proprietary BionicMimics™ platform for developing novel mimetic antibodies targeting inflammatory and autoimmune diseases.

Faces dual competition: as a drug developer against large pharma and biotechs in the crowded autoimmune space, and as a CDMO against global giants and specialized firms. Differentiation hinges on platform innovation and nimble, integrated service.